866-997-4948(US-Canada Toll Free)

Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020

Published By :

GlobalData

Published Date : Feb 2012

Category :

Ovarian Cancer

No. of Pages : 438 Pages


GlobalData, the industry analysis specialist, has released its new report, Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020. The report is an essential source of information and analysis on the global ovarian cancer therapeutics market. The report provides comprehensive information on ovarian cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global ovarian cancer therapeutics market. It analyses the treatment usage patterns in the global ovarian cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global ovarian cancer sector. It quantifies the unmet need in the global ovarian cancer therapeutics market as well as in the individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

The ovarian cancer therapeutics market grew at a Compound Annual Growth Rate (CAGR) of only 1.0% between 2002 and 2011. The patent expiries of major branded products, such as Taxol (paclitaxel), Paraplatin (carboplatin), Gemzar (gemcitabine), Hycamtin (topotecan hydrochloride) and the subsequent launch of generics, have acted as restraining factors to the market. The introduction of new and promising therapies such as Avastin (bevacizumab), AMG 386, EC145, Farletuzumab (MORAb-003), Karenitecin (BNP1350), OPAXIO (paclitaxel poliglumex), OPT-821, Paclical (paclitaxel), Vargatef (BIBF 1120) and Votrient (pazopanib) are expected to drive the market from 20112020.
In 2011, the ovarian cancer therapeutics markets in key countries (the US, the UK, Germany, France, Italy, Spain, Japan, Brazil, Russia, India and China) were worth $736.7m collectively. The ovarian cancer therapeutics market is expected to witness three-fold growth by 2020, reaching $2,352m at a CAGR of 13.8%. This high growth rate is expected due to the strength of the pipeline candidates, which are anticipated to change the treatment paradigm of ovarian cancer when launched.

Scope

The scope of the report includes -

 

  • An overview of ovarian cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized global ovarian cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data by stage of the disease from 2002 to 2010, forecast for 10 years to 2020. 
  • Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France Japan and BRIC countries that include Brazil, Russia, India and China
  • Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events. 
  • Competitor assessment including drug launch analysis and drug sales forecasts.
  • Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM activities, product positioning and drug sales forecast.
  • Analysis of unmet need in the market and target product profile including opportunity for target product. 
  • Technology trends analytic framework to assess strength of pipeline. 
  • Pipeline analysis data providing a split by stage of the disease and line of therapy across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include microtubule stabilizers, vascular endothelial growth factor receptor (VEGFR) inhibitors, immunomodulators, folate receptor inhibitors, poly ADP ribose polymerase (PARP) inhibitors, topoisomerase inhibitors, interleukins, mammalian target of rapamycin (mTOR) inhibitors and phosphatidylinositol-3-kinase (PI3K) inhibitors.
  • Clinical trials mapping of trials for ovarian cancer in different regions. 
  • An overview of the most promising drugs including clinical study details, efficacy, safety, collaboration agreements, marketing rights, and launch analysis and drug sales forcasts to 2020.
  • Analysis of the current and future market competition in the global ovarian cancer therapeutics market. 
  • Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Amgen Inc, AstraZeneca PLC, Boehringer Ingelheim GmbH, Oasmia Pharmaceutical AB, Endocyte, Inc, BioNumerik Pharmaceuticals, Inc, Eisai Inc., Cell Therapeutics, Inc, and Menarini Group, 
  • Analysis of licensing agreements during 2008-2010 in the ovarian cancer therapeutics market. M&A analysis which includes M&A deals by size and geography.
  • Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
  • Direct quotes from key opinion leaders (KOL) or physicians in the ovarian cancer therapeutics market.


Reasons to buy

The report will enhance your decision making capability. It will allow you to -

 

 

  • Develop business strategies and perform superior market quantification analysis by 
  • Understanding the trends shaping and driving the global ovarian cancer therapeutics market. 
  • Understanding treatment preferences of physicians in disease state and across treatment flow.
  • Accessing market sizing, forecasts and quantified growth opportunities in the global ovarian cancer therapeutics market till 2020.
  • Quantifying patient population in the global ovarian cancer market to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
  • performing benchmarking analysis and growth opportunities against currently marketed products
  • Identifying market entry points based on safety, efficacy, and pricing parameters. 
  • Assessing competitiveness of products in market by understanding the strength and weakness of current competition. 
  • Develop and design your in-licensing and out-licensing strategies by 
  • Taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.
  • Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.
  • Track drug sales in the global ovarian cancer therapeutics market from 2002 to 2020
  • Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
  • Whats the next big thing in the global ovarian cancer therapeutics market landscape? Identify, understand and capitalize.


Keywords

Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies, strategic competitor assessment, market characterization, implications for future market, mechanism of action, oncology, cancer, treatment guideline, target product profile, clinician's endpoints, disease overview, colorectal cancer drug sales, US colorectal cancer market, UK colorectal cancer market, France colorectal cancer market, Germany colorectal cancer market, Italy colorectal cancer market, Spain colorectal cancer market, Japan colorectal cancer market, BRIC colorectal cancer market, Brazil, Russia, India, China

 

Table of Contents

 

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 8

1.2 List of Figures 11

 

2 Ovarian Cancer Therapeutics - Disease Overview 16

2.1 Overview 16

2.1.1 Types of Ovarian Cancer 16

2.2 Staging and Treatment of Ovarian Cancer 17

2.2.1 Stage I 21

2.2.2 Stage IA 21

2.2.3 Stage IB 21

2.2.4 Stage IC 21

2.2.5 Stage II 21

2.2.6 Stage IIA 21

2.2.7 Stage IIB 21

2.2.8 Stage IIC 21

2.2.9 Stage III 22

2.2.10 Stage IIIA 22

2.2.11 Stage IIIB 22

2.2.12 Stage IV 22

2.3 Epidemiology 22

2.4 Etiology 22

2.5 Symptoms 23

2.6 Risk Factors 23

2.7 Diagnosis 24

2.7.1 Physical Examination 24

2.7.2 Blood Tests 24

2.7.3 Human Chorionic Gonadotropin (hCG) Test 26

2.7.4 Ultrasound and CT Scans 26

2.7.5 Biopsy 26

2.8 Pathology 27

2.8.1 Grading 27

2.9 Prognosis 27

2.10 Treatment 28

2.10.1 Surgery 28

2.10.2 Chemotherapy 29

2.10.3 Radiation Therapy 29

2.11 Treatment Options by Stage 29

2.11.1 Stage IA 29

2.11.2 Stage IB 29

2.11.3 Stage IC 30

2.11.4 Stage IIA 30

2.11.5 Stage IIB, Stage IIC, Stage IIIA, Stage, IIIB, Stage IIIC, Stage IV 30

2.11.6 Treatment Follow-Up 30

2.12 Chemotherapy Regimens 32

2.13 GlobalData In-Depth Report Guidance 33

 

3 Ovarian Cancer Therapeutics - Market Characterization 34

3.1 Global 34

3.1.1 Market Size 34

3.1.2 Drivers and Restraints 42

3.1.3 Forecasts 45

3.1.4 Drug Sales 54

3.2 The US 56

3.2.1 Market Size 56

3.2.2 Drivers and Restraints 63

3.2.3 Forecasts 66

3.2.4 Drug Sales 73

3.2.5 Pricing and Reimbursements 75

3.3 The UK 76

3.3.1 Market Size 76

3.3.2 Drivers and Restraints 84

3.3.3 Forecasts 87

3.3.4 Drug Sales 96

3.3.5 Pricing and Reimbursements 98

3.4 Germany 99

3.4.1 Market Size 99

3.4.2 Drivers and Restraints 107

3.4.3 Forecasts 110

3.4.4 Drug Sales 119

3.4.5 Pricing and Reimbursements 121

3.5 France 122

3.5.1 Market Size 122

3.5.2 Drivers and Restraints 130

3.5.3 Forecasts 132

3.5.4 Drug Sales 141

3.5.5 Pricing and Reimbursements 143

3.6 Italy 144

3.6.1 Market Size 144

3.6.2 Drivers and Restraints 152

3.6.3 Forecasts 155

3.6.4 Drug Sales 164

3.6.5 Pricing and Reimbursements 166

3.7 Spain 167

3.7.1 Market Size 167

3.7.2 Drivers and Restraints 175

3.7.3 Forecasts 178

3.7.4 Drug Sales 187

3.7.5 Pricing and Reimbursements 189

3.8 Japan 190

3.8.1 Market Size 190

3.8.2 Drivers and Restraints 198

3.8.3 Forecasts 201

3.8.4 Drug Sales 210

3.8.5 Pricing and Reimbursements 212

3.9 Brazil 213

3.9.1 Market Size 213

3.9.2 Patient Volume 216

3.9.3 Drivers and Restraints 220

3.9.4 Impact on the Market 222

3.9.5 Forecasts 223

3.9.6 Future Impact 229

3.10 Russia 230

3.10.1 Market Size 230

3.10.2 Drivers and Restraints 236

3.10.3 Impact on the Market 238

3.10.4 Forecasts 239

3.10.5 Future Impact 245

3.11 India 246

3.11.1 Market Size 246

3.11.2 Drivers and Restraints 253

3.11.3 Impact on the Market 255

3.11.4 Forecasts 256

3.11.5 Future Impact 263

3.12 China 264

3.12.1 Market Size 264

3.12.2 Drivers and Restraints 271

3.12.3 Impact on the Market 273

3.12.4 Forecasts 274

3.12.5 Future Impact 280

3.13 Key Takeaway 280

 

4 Ovarian Cancer Therapeutics - Opportunity and Unmet Need 281

4.1 Unmet Need 281

4.2 First-Line Treatment of Loco-Regional and Advanced/Metastatic Setting 282

4.3 Second-Line Treatment of Loco-Regional and Advanced/Metastatic Setting 283

4.4 Key Takeaway 283

 

5 Ovarian Cancer Therapeutics - Competitive Assessment 284

5.1 Strategic Competitor Assessment 284

5.1.1 Benchmarking 284

5.1.2 Current Competitor Assessment 292

5.1.3 Chemotherapy 293

 

6 Ovarian Cancer Therapeutics - Strategic Assessment 294

6.1 Key Events Impacting the Future Market 294

6.2 Market Impact Analysis 295

6.3 Future Market Scenario 296

 

7 Product Profiles for the Major Marketed Products in the Ovarian Cancer Market 297

7.1.1 Carboplatin 297

7.1.2 Cisplatin 304

7.1.3 Paclitaxel 308

7.1.4 Altretamine 314

7.1.5 Hycamtin (topotecan hydrochloride) 317

7.1.6 Gemzar (gemcitabine) 322

7.1.7 Yondelis (trabectedin) 326

7.1.8 Doxil (doxorubicin Hcl liposome injection) 331

7.2 Partners in Commercialization 336

7.2.1 Taj Pharmaceuticals Enters Into License Agreement with AstraZeneca Pharmaceuticals for Gemcitabine HCI 336

7.2.2 APP Pharmaceuticals Enters Into Licensing Agreement with Teva Pharmaceutical for Gemcitabine HCI 336

7.3 Key Takeaway 336

 

8 Ovarian Cancer - Pipeline Assessment 337

8.1 Overview 337

8.2 Pipeline Analysis by Phase of Development 337

8.3 Pipeline by Mechanism of Action 338

8.4 Pipeline by Line of Therapy 339

8.5 Strategic Pipeline Assessment 340

8.5.1 Technology Trends Analytic Framework 340

8.6 Ovarian Cancer Pipeline – Pipeline by Clinical Phases of Development 342

8.6.1 Ovarian Cancer – Pre-Registration Clinical Pipeline 342

8.6.2 Ovarian Cancer – Phase III of the Clinical Pipeline 343

8.6.3 Ovarian Cancer – Phase II of the Clinical Pipeline 344

8.6.4 Ovarian Cancer – Phase I of the Clinical Pipeline 348

8.6.5 Ovarian Cancer – Preclinical Pipeline 350

8.6.6 Ovarian Cancer – Discovery Stage Pipeline 351

8.7 Most Promising Drug Profiles 351

8.7.1 Avastin (bevacizumab) 351

8.7.2 Paclical (paclitaxel) 354

8.7.3 Votrient (pazopanib) 355

8.7.4 Farletuzumab (MORAb-003) 357

8.7.5 Karenitecin (BNP 1350) 359

8.7.6 Opaxio (xyotax, CT-2103) 361

8.7.7 AMG 386 364

8.7.8 EC-145 365

8.7.9 Recentin (cediranib, AZD2171) 367

8.7.10 Vargatef (BIBF 1120) 368

8.8 Partners in Research and Development 370

8.8.1 Licensing Agreements 370

8.8.2 Co-development Agreements 372

8.9 Key Takeaway 375

 

9 Ovarian Cancer Therapeutics - Clinical Trials Mapping 376

9.1 Clinical Trials 376

9.1.1 Clinical Trials by Status 376

9.1.2 Clinical Trials by Country 377

9.1.3 Clinical Trials by Phase 378

9.1.4 Clinical Trials by Sponsor Type 379

9.1.5 Clinical Trials – Leading Sponsors 380

9.1.6 Clinical Trials – Leading Company Sponsors by Phase 381

9.2 Patient Recruitment 382

 

10 Ovarian Cancer Therapeutics - Future Market Players 383

10.1 F. Hoffmann-La Roche Ltd. 383

10.1.1 Business Description 383

10.1.2 Financial Overview 383

10.1.3 SWOT Analysis 384

10.2 Menarini Group 389

10.2.1 Business Description 389

10.2.2 Financial Overview 389

10.2.3 SWOT Analysis 390

10.3 GlaxoSmithKline plc. 394

10.3.1 Business Description 394

10.3.2 Financial Overview 394

10.3.3 SWOT Analysis 395

10.4 Eisai Inc., 400

10.4.1 Business Description 400

10.4.2 Financial Overview 401

10.4.3 SWOT Analysis 401

10.5 Cell Therapeutics, Inc. 404

10.5.1 Business Description 404

10.5.2 Financial Overview 404

10.5.3 SWOT Analysis 405

10.6 Amgen Inc. 408

10.6.1 Business Description 408

10.6.2 Financial Overview 409

10.6.3 SWOT Analysis 410

10.7 AstraZeneca PLC 414

10.7.1 Business Description 414

10.7.2 Financial Overview 415

10.7.3 SWOT Analysis 415

10.8 Boehringer Ingelheim GmbH 419

10.8.1 Business Description 419

10.8.2 Financial Overview 419

10.8.3 SWOT Analysis 420

10.9 Oasmia Pharmaceutical AB 424

10.9.1 Business Description 424

10.9.2 Financial Overview 424

10.10 Endocyte, Inc. 424

10.10.1 Business Description 424

10.11 BioNumerik Pharmaceuticals, Inc. 424

10.11.1 Business Description 424

 

11 Ovarian Cancer Therapeutics - M&A Analysis 425

11.1 Key Highlights 425

11.1.1 M&A Agreements by Phase of Development 425

 

12 Ovarian Cancer Therapeutics - Expert Opinion 427

12.1 Important Data and Analysis from Key Opinion Leaders (KOLs) 427

12.1.1 Treatment Options (Surgery/Chemotherapy) 427

12.1.2 Treatment Options by Stage 427

12.1.3 Number of Chemotherapy Cycles 428

12.1.4 Future Therapies for Ovarian Cancer Treatment 428

12.1.5 Future Growth Rate of the Ovarian Cancer Market 428

12.1.6 Current Unmet Needs for Ovarian Cancer Treatment 428

12.1.7 What Ideal Features are Required in a New Drug 428

12.1.8 Past Patient Trends in Ovarian Cancer 428

12.1.9 Referral Pathway 428

 

13 Ovarian Cancer Therapeutics - Appendix 429

13.1 Definitions 429

13.2 Acronyms 429

13.3 Research Methodology 432

13.3.1 Coverage 433

13.3.2 Secondary Research 433

13.3.3 Forecasting 433

13.3.4 Primary Research 435

13.3.5 Expert Panel Validation 436

13.4 Contact Us 436

13.5 Disclaimer 436

13.6 Sources 436

List of Table


Table 1: Ovarian Cancer, AJCC TNM and FIGO Staging System 17
Table 2: Ovarian Cancer, Classification and Treatment Protocol Stages 18
Table 3: Ovarian Cancer Stages I, II & III 20
Table 4: Ovarian Cancer Stage IV 21
Table 5: Ovarian Cancer, Classification of Ovarian Cancer, 2011 27
Table 6: Ovarian Cancer Five-Year Survival Rates 27
Table 7: Ovarian Cancer Chemotherapy Regimens 32
Table 8:Ovarian Cancer Therapeutics Market, Global, Sales Value ($m) by Country, 20022011 36
Table 9: Ovarian Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 20022011 38
Table 10: Ovarian Cancer Therapeutics Market, Global, Patient Volume, 20022011 40
Table 11: Ovarian Cancer Therapeutics Market, Global, Treatment Usage Patterns, 20022011 41
Table 12: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m), 20112020 45
Table 13: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m), 20112020 47
Table 14: Ovarian Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 20112020 48
Table 15: Ovarian Cancer Therapeutics Market, Global, Patient Volume, 20112020 50
Table 16: Ovarian Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2011-2020 52
Table 17: Ovarian Cancer Therapeutics Market, Top Seven Countries, Drug Sales ($m), 20022011 54
Table 18: Ovarian Cancer Therapeutics Market, Top Seven Countries, Drug Sales ($m), 20112020 55
Table 19: Ovarian Cancer Therapeutics Market, The US, Sales Value ($m), 20022011 56
Table 20: Ovarian Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 20022011 58
Table 21: Ovarian Cancer Therapeutics Market, The US, Patient Volume, 20022011 60
Table 22: Ovarian Cancer Therapeutics Market, The US, Treatment Usage Patterns, 20022011 61
Table 23: Ovarian Cancer Therapeutics Market, The US, Sales Value ($m), 20112020 66
Table 24: Ovarian Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 20112020 68
Table 25: Ovarian Cancer Therapeutics Market, The US, Patient Volume, 20112020 70
Table 26: Ovarian Cancer Therapeutics Market, The US, Treatment Usage Patterns, 20112020 71
Table 27: Ovarian Cancer Therapeutics Market, The US, Drug Sales ($m), 20022011 73
Table 28: Ovarian Cancer Therapeutics Market, The US, Drug Sales ($m), 20112020 74
Table 29: Ovarian Cancer Therapeutics Market, The UK, Sales Value ($m), 20022011 76
Table 30: Ovarian Cancer Therapeutics Market, The UK, Annual Cost of Therapy ($), 20022011 78
Table 31: Ovarian Cancer Therapeutics Market, The UK, Patient Volume, 20022011 80
Table 32: Ovarian Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 20022011 82
Table 33: Ovarian Cancer Therapeutics Market, The UK, Sales Value ($m), 20112020 87
Table 34: Ovarian Cancer Therapeutics Market, the UK, Annual Cost of Therapy ($), 20112020 89
Table 35: Ovarian Cancer Therapeutics Market, The UK, Patient Volume, 20112020 91
Table 36: Ovarian Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 20112020 93
Table 37: Ovarian Cancer Therapeutics Market, The UK, Drug Sales ($m), 20022011 96
Table 38: Ovarian Cancer Therapeutics Market, The UK, Drug Sales ($m), 20112020 97
Table 39: Ovarian Cancer Therapeutics Market, Germany, Sales Value ($m), 20022011 99
Table 40: Ovarian Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 20022011 101
Table 41: Ovarian Cancer Therapeutics Market, Germany, Patient Volume, 20022011 103
Table 42: Ovarian Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 20022011 105
Table 43: Ovarian Cancer Therapeutics Market, Germany, Sales Value ($m), 20112020 110
Table 44: Ovarian Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 20112020 112
Table 45: Ovarian Cancer Therapeutics Market, Germany, Patient Volume, 20112020 114
Table 46: Ovarian Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 20112020 116
Table 47: Ovarian Cancer Therapeutics Market, Germany, Drug Sales ($m), 20022011 119
Table 48: Ovarian Cancer Therapeutics Market, Germany, Drug Sales ($m), 20112020 120
Table 49: Ovarian Cancer Therapeutics Market, France, Sales Value ($m), 20022011 122
Table 50: Ovarian Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 20022011 124
Table 51: Ovarian Cancer Therapeutics Market, France, Patient Volume, 20022011 126
Table 52: Ovarian Cancer Therapeutics Market, France, Treatment Usage Patterns, 20022011 128
Table 53: Ovarian Cancer Therapeutics Market, France, Sales Value ($m), 20112020 132
Table 54: Ovarian Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 20112020 134
Table 55: Ovarian Cancer Therapeutics Market, France, Patient Volume, 20112020 136
Table 56: Ovarian Cancer Therapeutics Market, France, Treatment Usage Patterns, 20112020 138
Table 57: Ovarian Cancer Therapeutics Market, France, Drug Sales ($m), 20022011 141
Table 58: Ovarian Cancer Therapeutics Market, France, Drug Sales ($m), 20112020 142
Table 59: Ovarian Cancer Therapeutics Market, Italy, Sales Value ($m), 20022011 144
Table 60: Ovarian Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 20022011 146
Table 61: Ovarian Cancer Therapeutics Market, Italy, Patient Volume, 20022011 148
Table 62: Ovarian Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 20022011 150
Table 63: Ovarian Cancer Therapeutics Market, Italy, Sales Value ($m), 20112020 155
Table 64: Ovarian Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 20112020 157
Table 65: Ovarian Cancer Therapeutics Market, Italy, Patient Volume, 20112020 159
Table 66: Ovarian Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 20112020 161
Table 67: Ovarian Cancer Therapeutics Market, Italy, Drug Sales ($m), 20022011 164
Table 68: Cancer Therapeutics Market, Italy, Drug Sales ($m), 20112020 165
Table 69: Ovarian Cancer Therapeutics Market, Spain, Sales Value ($m), 20022011 167
Table 70: Ovarian Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 20022011 169
Table 71: Ovarian Cancer Therapeutics Market, Spain, Patient Volume, 20022011 171
Table 72: Ovarian Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 20022011 173
Table 73: Ovarian Cancer Therapeutics Market, Spain, Sales Value ($m), 20112020 178
Table 74: Ovarian Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 20112020 180
Table 75: Ovarian Cancer Therapeutics Market, Spain, Patient Volume, 20112020 182
Table 76: Ovarian Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 20112020 184
Table 77: Ovarian Cancer Therapeutics Market, Spain, Drug Sales ($m), 20022011 187
Table 78: Ovarian Cancer Therapeutics Market, Spain, Drug Sales ($m), 20112020 188
Table 79: Ovarian Cancer Therapeutics Market, Japan, Drug Sales ($m), 2002-2011 190
Table 80: Ovarian Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 20022011 192
Table 81: Ovarian Cancer Therapeutics Market, Japan, Patient Volume, 20022011 194
Table 82: Ovarian Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 20022011 196
Table 83: Ovarian Cancer Therapeutics Market, Japan, Sales Value ($m), 20112020 201
Table 84: Ovarian Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 20112020 203
Table 85: Ovarian Cancer Therapeutics Market, Japan, Patient Volume, 20112020 205
Table 86: Ovarian Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 20112020 207
Table 87: Ovarian Cancer Therapeutics Market, Japan, Drug Sales ($m), 20022011 210
Table 88: Ovarian Cancer Therapeutics Market, Japan, Drug Sales ($m), 20112020 211
Table 89: Ovarian Cancer Therapeutics Market, Brazil, Sales Value ($m), 20022011 213
Table 90: Ovarian Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 20022011 215
Table 91: Ovarian Cancer Therapeutics Market, Brazil, Patient Volume, 20022011 216
Table 92: Ovarian Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 20022011 218
Table 93: Ovarian Cancer Therapeutics Market, Brazil, Sales Value ($m), 20112020 223
Table 94: Ovarian Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 20112020 225
Table 95: Ovarian Cancer Therapeutics Market, Brazil, Patient Volume , 20112020 226
Table 96: Ovarian Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 20112020 228
Table 97: Ovarian Cancer Therapeutics Market, Russia, Sales Value ($m), 20022011 230
Table 98: Ovarian Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 20022011 231
Table 99: Ovarian Cancer Therapeutics Market, Russia, Patient Volume (Absolute), 20022011 232
Table 100: Ovarian Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 20022011 234
Table 101: Ovarian Cancer Therapeutics Market, Russia, Sales Value ($m), 20112020 239
Table 102: Ovarian Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 20112020 240
Table 103: Ovarian Cancer Therapeutics Market, Russia, Patient Volume (Absolute), 20112020 241
Table 104: Ovarian Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 20112020 243
Table 105: Ovarian Cancer Therapeutics Market, India, Sales Value ($m), 20022011 246
Table 106: Ovarian Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 20022011 248
Table 107: Ovarian Cancer Therapeutics Market, India, Patient Volume (Absolute), 20022011 249
Table 108: Ovarian Cancer Therapeutics Market, India, Treatment Usage Patterns, 20022011 251
Table 109: Ovarian Cancer Therapeutics Market, India, Sales Value ($m), 20112020 256
Table 110: Ovarian Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 20112020 258
Table 111: Ovarian Cancer Therapeutics Market, India, Patient Volume (Absolute), 20112020 259
Table 112: Ovarian Cancer Therapeutics Market, India, Treatment Usage Patterns, 20112020 261
Table 113: Ovarian Cancer Therapeutics Market, China, Sales Value ($m), 20022011 264
Table 114: Ovarian Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 20022011 266
Table 115: Ovarian Cancer Therapeutics Market, China, Patient Volume (Absolute), 20022011 267
Table 116: Ovarian Cancer Therapeutics Market, China, Treatment Usage Patterns, 20022011 269
Table 117: Ovarian Cancer Therapeutics Market, China, Sales Value ($m), 20112020 274
Table 118: Ovarian Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 20112020 276
Table 119: Ovarian Cancer Therapeutics Market, China, Patient Volume (Absolute), 20112020 277
Table 120: Ovarian Cancer Therapeutics Market, China, Treatment Usage Patterns, 20112020 279
Table 121: Ovarian Cancer, Global, Clinical Endpoints Approved Drugs, 2011 284
Table 122:Ovarian Cancer, Global, Clinical Endpoints for Benchmarking, First-Line Loco-Regional and Advanced/Metastatic Setting, 2011 285
Table 123: Ovarian Cancer, Global, Clinical Endpoints for Benchmarking, Second-Line Loco-Regional and Advanced/Metastatic Setting, 2011 285
Table 124:Ovarian Cancer Therapeutics , Global, Safety Profile of Approved Treatment in Loco-Regional and Advanced/Metastatic Setting, 2011 292
Table 125:Ovarian Cancer Therapeutics Market, Global, Carboplatin, Incidence of Adverse Effects NCIC Study, 2011 298
Table 126:Ovarian Cancer Therapeutics Market, Global, Carboplatin, Incidence of Adverse Effects SWOG Study, 2011 299
Table 127:Ovarian Cancer Therapeutics Market, Global, Carboplatin, Overview of Pivotal Trials, 2011 300
Table 128:Ovarian Cancer Therapeutics Market, Global, Carboplatin, Progression Free Survival, 2011 301
Table 129: Ovarian Cancer Therapeutics Market, Global, Carboplatin, Overall Survival, 2011 301
Table 130:Ovarian Cancer Therapeutics Market, Global, Paclitaxel, Incidence of Adverse Effects in the First-Line Treatment, 2011 309
Table 131:Ovarian Cancer Therapeutics Market, Global, Paclitaxel Incidence of Adverse Effects in the Second-Line Treatment, 2011 310
Table 132:Ovarian Cancer Therapeutics Market, Global, Altretamine, Incidence of Adverse Effects, 2011 315
Table 133:Ovarian Cancer Therapeutics, Hycamtin, Incidence of Adverse Effects, 2011 318
Table 134: Ovarian Cancer Therapeutics , Gemzar, Incidence of Adverse Effects, 2011 323
Table 135:Ovarian Cancer Therapeutics Market, Global, Yondelis, Incidence of Adverse Effects, 2011 327
Table 136: Ovarian Cancer Therapeutics Market, Global, Doxil, Incidence of Adverse Effects, 2011 332
Table 137: Ovarian Cancer, Global, Pipeline by Line of Therapy, 2011 339
Table 138: Ovarian Cancer Pipeline, Pre-Registration, 2011 342
Table 139: Ovarian Cancer Pipeline, Phase III, 2011 343
Table 140: Ovarian Cancer Pipeline, Phase II, 2011 344
Table 141: Ovarian Cancer Pipeline, Phase I, 2011 348
Table 142: Ovarian Cancer Pipeline, Prelinical, 2011 350
Table 143: Ovarian Cancer Pipeline, Discovery, 2011 351
Table 144: Ovarian Cancer, Global, Licensing Agreements, 20092011 372
Table 145: Ovarian Cancer, Global, Co-development Agreements, 20092011 374
Table 146: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Status, March 2011 376
Table 147: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Country, March 2011 377
Table 148: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Phase, March 2011 378
Table 149:Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, March 2011 379
Table 150:Ovarian Cancer Therapeutics Market, Global, Clinical Trials, Leading Sponsors, March 2011 380
Table 151:Ovarian Cancer Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, March 2011 381
Table 152:Ovarian Cancer Therapeutics Market, Global, Clinical Trials, Average Number of Patients Recruited, March 2011 382
Table 153: Ovarian Cancer, Global, M&A Deals by Geography, 20092011 426
Table 154: Ovarian Cancer Therapeutics Market, Global, Treatment Options by Stage, 2011 427

List of Chart


Figure 1: Ovarian Cancer, Treatment Algorithm, Stage I and II 31
Figure 2: Ovarian Cancer, Treatment Algorithm, Stage III and IV 31
Figure 3: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m), 20022011 34
Figure 4: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m) by Country, 20022011 36
Figure 5: Ovarian Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 20022011 38
Figure 6: Ovarian Cancer Therapeutics Market, Global, Patient Volume, 20022011 39
Figure 7: Ovarian Cancer Therapeutics Market, Global, Treatment Usage Patterns, 20022011 41
Figure 8: Ovarian Cancer Therapeutics Market, Global, Market Drivers and Restraints, 2011 42
Figure 9: Ovarian Cancer Therapeutics Market, Global, the Impact of Historical Events on the Market, 2011 44
Figure 10: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m), 20112020 45
Figure 11: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m) by Country, 20112020 46
Figure 12: Ovarian Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 20112020 48
Figure 13: Ovarian Cancer Therapeutics Market, Global, Patient Volume, 20112020 50
Figure 14: Ovarian Cancer Therapeutics Market, Global, Treatment Usage Patterns, 20112020 52
Figure 15: Ovarian Cancer Therapeutics Market, Global, Future Market Drivers and Restraints, 20112020 53
Figure 16: Ovarian Cancer Therapeutics Market, Top Seven Countries, Drug Sales ($m), 2002-2020 54
Figure 17: Ovarian Cancer Therapeutics Market, The US, Sales Value ($m), 20022011 56
Figure 18: Ovarian Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 20022011 58
Figure 19: Ovarian Cancer Therapeutics Market, The US, Patient Volume (absolute), 20022011 60
Figure 20: Ovarian Cancer Therapeutics Market, The US, Treatment Usage Patterns, 20022011 61
Figure 21: Ovarian Cancer Therapeutics Market, The US, Market Drivers and Restraints, 2011 63
Figure 22: Ovarian Cancer Therapeutics Market, The US, The Impact of Historical Events on the Market, 2011 65
Figure 23: Ovarian Cancer Therapeutics Market, The US, Sales Value ($m), 20112020 66
Figure 24: Ovarian Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 20112020 68
Figure 25: Ovarian Cancer Therapeutics Market, The US, Patient Volume (Absolute), 20112020 70
Figure 26: Ovarian Cancer Therapeutics Market, The US, Treatment Usage Patterns, 20112020 71
Figure 27: Ovarian Cancer Therapeutics Market, The US, Future Market Drivers and Restraints, 20112020 72
Figure 28: Ovarian Cancer Therapeutics Market, The US, Drug Sales ($m), 2002-2020 73
Figure 29: Ovarian Cancer Therapeutics Market, The UK, Sales Value ($m), 20022011 76
Figure 30: Ovarian Cancer Therapeutics Market, The UK, Annual Cost of Therapy ($), 20022011 78
Figure 31: Ovarian Cancer Therapeutics Market, The UK, Patient Volume (Absolute), 20022011 80
Figure 32: Ovarian Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 20022011 82
Figure 33: Ovarian Cancer Therapeutics Market, The UK, Market Drivers and Restraints, 2011 84
Figure 34: Ovarian Cancer Therapeutics Market, The UK, The Impact of Historical Events on the Market, 2011 86
Figure 35: Ovarian Cancer Therapeutics Market, The UK, Sales Value ($m), 20112020 87
Figure 36: Ovarian Cancer Therapeutics Market, The UK, Annual Cost of Therapy ($), 20112020 89
Figure 37: Ovarian Cancer Therapeutics Market, The UK, Patient Volume (Absolute), 20112020 91
Figure 38: Ovarian Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 20112020 93
Figure 39: Ovarian Cancer Therapeutics Market, The UK, Future Market Drivers and Restraints, 20112020 95
Figure 40: Ovarian Cancer Therapeutics Market, The UK, Drug Sales ($m), 2002-2020 96
Figure 41: Ovarian Cancer Therapeutics Market, Germany, Sales Value ($m), 20022011 99
Figure 42: Ovarian Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 20022011 101
Figure 43: Ovarian Cancer Therapeutics Market, Germany, Patient Volume (Absolute), 20022011 103
Figure 44: Ovarian Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 20022011 105
Figure 45: Ovarian Cancer Therapeutics Market, Germany, Market Drivers and Restraints, 2011 107
Figure 46: Ovarian Cancer Therapeutics Market, Germany, The Impact of Historical Events on the Market, 2011 109
Figure 47: Ovarian Cancer Therapeutics Market, Germany, Sales Value ($m), 20112020 110
Figure 48: Ovarian Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 20112020 112
Figure 49: Ovarian Cancer Therapeutics Market, Germany, Patient Volume (Absolute), 20112020 114
Figure 50: Ovarian Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 20112020 116
Figure 51: Ovarian Cancer Therapeutics Market, Germany, Future Market Drivers and Restraints, 20112020 118
Figure 52: Ovarian Cancer Therapeutics Market, Germany, Drug Sales ($m), 2002-2020 119
Figure 53: Ovarian Cancer Therapeutics Market, France, Sales Value ($m), 20022011 122
Figure 54: Ovarian Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 20022011 124
Figure 55: Ovarian Cancer Therapeutics Market, France, Patient Volume (Absolute), 20022011 126
Figure 56: Ovarian Cancer Therapeutics Market, France, Treatment Usage Patterns, 20022011 128
Figure 57: Ovarian Cancer Therapeutics Market, France, Market Drivers and Restraints, 2011 130
Figure 58: Ovarian Cancer Therapeutics Market, France, The Impact of Historical Events on the Market, 2011 131
Figure 59: Ovarian Cancer Therapeutics Market, France, Sales Value ($m), 20112020 132
Figure 60: Ovarian Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 20112020 134
Figure 61: Ovarian Cancer Therapeutics Market, France, Patient Volume (Absolute), 20112020 136
Figure 62: Ovarian Cancer Therapeutics Market, France, Treatment Usage Patterns, 20112020 138
Figure 63: Ovarian Cancer Therapeutics Market, France, Future Market Drivers and Restraints, 20112020 140
Figure 64: Ovarian Cancer Therapeutics Market, France, Drug Sales ($m), 20022020 141
Figure 65: Ovarian Cancer Therapeutics Market, Italy, Sales Value ($m), 20022011 144
Figure 66: Ovarian Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 20022011 146
Figure 67: Ovarian Cancer Therapeutics Market, Italy, Patient Volume (Absolute), 20022011 148
Figure 68: Ovarian Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 20022011 150
Figure 69: Ovarian Cancer Therapeutics Market, Italy, Market Drivers and Restraints, 2011 152
Figure 70: Ovarian Cancer Therapeutics Market, Italy, The Impact of Historical Events on the Market, 2011 154
Figure 71: Ovarian Cancer Therapeutics Market, Italy, Sales Value ($m), 20112020 155
Figure 72: Ovarian Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 20112020 157
Figure 73: Ovarian Cancer Therapeutics Market, Italy, Patient Volume (Absolute), 20112020 159
Figure 74: Ovarian Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 20112020 161
Figure 75: Ovarian Cancer Therapeutics Market, Italy, Future Market Drivers and Restraints, 20112020 163
Figure 76: Ovarian Cancer Therapeutics Market, Italy, Drug Sales ($m), 2002-2020 164
Figure 77: Ovarian Cancer Therapeutics Market, Spain, Sales Value ($m), 20022011 167
Figure 78: Ovarian Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 20022011 169
Figure 79: Ovarian Cancer Therapeutics Market, Spain, Patient Volume (Absolute), 20022011 171
Figure 80: Ovarian Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 20022011 173
Figure 81: Ovarian Cancer Therapeutics Market, Spain, Market Drivers and Restraints, 2011 175
Figure 82: Ovarian Cancer Therapeutics Market, Spain, The Impact of Historical Events on the Market, 2011 177
Figure 83: Ovarian Cancer Therapeutics Market, Spain, Sales Value ($m), 20112020 178
Figure 84: Ovarian Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 20112020 180
Figure 85: Ovarian Cancer Therapeutics Market, Spain, Patient Volume (Absolute), 20112020 182
Figure 86: Ovarian Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 20112020 184
Figure 87: Ovarian Cancer Therapeutics Market, Spain, Future Market Drivers and Restraints, 20112020 186
Figure 88: Ovarian Cancer Therapeutics Market, Spain, Drug Sales ($m), 2002-2020 187
Figure 89: Ovarian Cancer Therapeutics Market, Japan, Drug Sales ($m), 2002-2011 190
Figure 90: Ovarian Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 20022011 192
Figure 91: Ovarian Cancer Therapeutics Market, Japan, Patient Volume (Absolute), 20022011 194
Figure 92: Ovarian Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 20022011 196
Figure 93: Ovarian Cancer Therapeutics Market, Japan, Market Drivers and Restraints, 2011 198
Figure 94: Ovarian Cancer Therapeutics Market, Japan, Impact of Historical Events on the Market, 2011 200
Figure 95: Ovarian Cancer Therapeutics Market, Japan, Sales Value ($m), 20112020 201
Figure 96: Ovarian Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 20112020 203
Figure 97: Ovarian Cancer Therapeutics Market, Japan, Patient Volume (Absolute), 20112020 205
Figure 98: Ovarian Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 20112020 207
Figure 99: Ovarian Cancer Therapeutics Market, Japan, Future Market Drivers and Restraints, 20112020 209
Figure 100: Ovarian Cancer Therapeutics Market, Japan, Drug Sales ($m), 2002-2020 210
Figure 101: Ovarian Cancer Therapeutics Market, Brazil, Sales Value ($m), 20022011 213
Figure 102: Ovarian Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 20022011 215
Figure 103: Ovarian Cancer Therapeutics Market, Brazil, Patient Volume (Absolute), 20022011 216
Figure 104: Ovarian Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 20022011 218
Figure 105: Ovarian Cancer Therapeutics Market, Brazil, Market Drivers and Restraints, 2011 220
Figure 106: Ovarian Cancer Therapeutics Market, Brazil, The Impact of Historical Events on the Market, 2011 222
Figure 107: Ovarian Cancer Therapeutics Market, Brazil, Sales Value ($m), 20112020 223
Figure 108: Ovarian Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 20112020 225
Figure 109: Ovarian Cancer Therapeutics Market, Brazil, Patient Volume (Absolute), 20112020 226
Figure 110: Ovarian Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 20112020 228
Figure 111: Ovarian Cancer Therapeutics Market, Brazil, Future Market Drivers and Restraints, 20112020 229
Figure 112: Ovarian Cancer Therapeutics Market, Russia, Sales Value ($m), 20022011 230
Figure 113: Ovarian Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 20022011 231
Figure 114: Ovarian Cancer Therapeutics Market, Russia, Patient Volume (Absolute), 20022011 232
Figure 115: Ovarian Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 20022011 234
Figure 116: Ovarian Cancer Therapeutics Market, Russia, Market Drivers and Restraints, 2011 236
Figure 117: Ovarian Cancer Therapeutics Market, Russia, The Impact of Historical Events on the Market, 2011 238
Figure 118: Ovarian Cancer Therapeutics Market, Russia, Sales Value ($m), 20112020 239
Figure 119: Ovarian Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 20112020 240
Figure 120: Ovarian Cancer Therapeutics Market, Russia, Patient Volume (Absolute), 20112020 241
Figure 121: Ovarian Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 20112020 243
Figure 122: Ovarian Cancer Therapeutics Market, Russia, Future Market Drivers and Restraints, 20112020 245
Figure 123: Ovarian Cancer Therapeutics Market, India, Sales Value ($m), 20022011 246
Figure 124: Ovarian Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 20022011 248
Figure 125: Ovarian Cancer Therapeutics Market, India, Patient Volume (Absolute), 20022011 249
Figure 126: Ovarian Cancer Therapeutics Market, India, Treatment Usage Patterns, 20022011 251
Figure 127: Ovarian Cancer Therapeutics Market, India, Market Drivers and Restraints, 2011 253
Figure 128: Ovarian Cancer Therapeutics Market, India, The Impact of Historical Events on the Market, 2011 255
Figure 129: Ovarian Cancer Therapeutics Market, India, Sales Value ($m), 20112020 256
Figure 130: Ovarian Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 20112020 258
Figure 131: Ovarian Cancer Therapeutics Market, India, Patient Volume (Absolute), 20112020 259
Figure 132: Ovarian Cancer Therapeutics Market, India, Treatment Usage Patterns, 20112020 261
Figure 133: Ovarian Cancer Therapeutics Market, India, Future Market Drivers and Restraints, 20112020 263
Figure 134: Ovarian Cancer Therapeutics Market, China, Sales Value ($m), 20022011 264
Figure 135: Ovarian Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 20022011 266
Figure 136: Ovarian Cancer Therapeutics Market, China, Patient Volume (Absolute), 20022011 267
Figure 137: Ovarian Cancer Therapeutics Market, China, Treatment Usage Patterns, 20022011 269
Figure 138: Ovarian Cancer Therapeutics Market, China, Market Drivers and Restraints, 2011 271
Figure 139: Ovarian Cancer Therapeutics Market, China, The Impact of Historical Events on the Market, 2011 273
Figure 140: Ovarian Cancer Therapeutics Market, China, Sales Value ($m), 20112020 274
Figure 141: Ovarian Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 20112020 276
Figure 142: Ovarian Cancer Therapeutics Market, China, Patient Volume (Absolute), 20112020 277
Figure 143: Ovarian Cancer Therapeutics Market, China, Treatment Usage Patterns, 20112020 279
Figure 144: Ovarian Cancer Therapeutics Market, China, Future Market Drivers and Restraints, 20112020 280
Figure 145: Ovarian Cancer, Global, Opportunity and Unmet Need in First-Line Treatment of Loco-Regional and Advanced/Metastatic Setting, 2011 282
Figure 146: Ovarian Cancer, Global, Opportunity and Unmet Need in Second-Line Treatment of Loco-Regional and Advanced/Metastatic Setting, 2011 283
Figure 147: Ovarian Cancer, Global, Response Rate in First-Line Loco-Regional and Advanced/Metastatic Setting, (%), 2011 285
Figure 148: Ovarian Cancer, Global, Overall Survival in First-Line Loco-Regional and Advanced/Metastatic Setting in Months, 2011 286
Figure 149: Ovarian Cancer, Global, Progression-free Survival in First-Line Loco-Regional and Advanced/Metastatic Setting in Months, 2011 287
Figure 150: Ovarian Cancer, Global, Response Rate in Second-Line Loco-Regional and Advanced/Metastatic Setting, (%) 2011 288
Figure 151: Ovarian Cancer, Global, Overall Survival in Second-Line Loco-Regional and Advanced/Metastatic Setting, (%), 2011 289
Figure 152: Ovarian Cancer, Global, Progression-Free Survival in Second-Line Loco-Regional and Advanced/Metastatic Setting in Months, 2011 290
Figure 153: Ovarian Cancer, Global, Time-to-Progression in Second-Line Loco-Regional and Advanced/Metastatic Setting in Months, 2011 291
Figure 154: Strategic Competitor Assessment of the Marketed Chemotherapy Products for Ovarian Cancer, 2011 293
Figure 155: Ovarian Cancer, Global, Key Events Impacting the Future Market, 2011 294
Figure 156: Ovarian Cancer, Global, Implications for Future Market Competition, 2011 296
Figure 157: Ovarian Cancer Therapeutics Market, Global, Carboplatin, Chemical Structure, 2011 297
Figure 158: Ovarian Cancer Therapeutics Market, Global, Carboplatin, Sales Forecast ($m), 2002-2020 302
Figure 159: Ovarian Cancer Therapeutics Market, Global, Carboplatin, Market Share Analysis (%), 2011 303
Figure 160: Ovarian Cancer Therapeutics Market, Global, Cisplatin, Chemical Structure, 2011 304
Figure 161: Ovarian Cancer Therapeutics Market, Global, Cisplatin, Sales Forecast ($m), 20022020 306
Figure 162: Ovarian Cancer Therapeutics Market, Global, Cisplatin, Market Share Analysis (%), 2011 307
Figure 163: Ovarian Cancer Therapeutics Market, Global, Paclitaxel, Chemical Structure, 2011 308
Figure 164: Ovarian Cancer Therapeutics Market, Global, Paclitaxel, Life Cycle Management Activities, 2011 311
Figure 165: Ovarian Cancer Therapeutics Market, Global, Paclitaxel, Sales Forecast ($m), 2002-2015 312
Figure 166: Ovarian Cancer Therapeutics Market, Global, Paclitaxel, Market Share Analysis (%), 2011 313
Figure 167: Ovarian Cancer Therapeutics Market, Global, Altretamine, Chemical Structure, 2011 314
Figure 168: Ovarian Cancer Therapeutics Market, Global, Altretamine, Life Cycle Management Activities, 2011 316
Figure 169: Ovarian Cancer Therapeutics Market, Global, Hycamtin, Chemical Structure, 2011 317
Figure 170: Ovarian Cancer Therapeutics Market, Global, Hycamtin, Life Cycle Management Activities, 2011 319
Figure 171: Ovarian Cancer Therapeutics Market, Global, Hycamtin, Sales Forecast ($m), 20022015 320
Figure 172: Ovarian Cancer Therapeutics Market, Global, Hycamtin, Market Share Analysis (%), 2011 321
Figure 173: Ovarian Cancer Therapeutics Market, Global, Gemzar, Chemical Structure, 2011 322
Figure 174: Ovarian Cancer Therapeutics Market, Global, Gemzar, Life Cycle Management Activities, 2011 324
Figure 175: Ovarian Cancer Therapeutics Market, Global, Gemzar, Sales Forecast ($m), 20042015 325
Figure 176: Ovarian Cancer Therapeutics Market, Global, Gemzar, Market Share Analysis (%), 2011 326
Figure 177: Ovarian Cancer Therapeutics Market, Global, Yondelis, Chemical Structure, 2011 327
Figure 178: Ovarian Cancer Therapeutics Market, Global, Yondelis, Life Cycle Management Activities, 2011 329
Figure 179: Ovarian Cancer Therapeutics Market, Global, Yondelis, Sales Forecast ($m), 20092020 329
Figure 180: Ovarian Cancer Therapeutics Market, Global, Yondelis, Market Share Analysis (%), 2011 330
Figure 181: Ovarian Cancer Therapeutics Market, Global, Doxil, Chemical Structure, 2011 331
Figure 182: Ovarian Cancer Therapeutics Market, Global, Doxil, Life Cycle Management Activities, 2011 333
Figure 183: Ovarian Cancer Therapeutics Market, Global, Doxil, Sales Forecast ($m), 2002-2016 334
Figure 184: Ovarian Cancer Therapeutics Market, Global, Doxil, Market Share Analysis (%), 2011 335
Figure 185: Ovarian Cancer, Global, Clinical Trials by Phase of Development, 2011 337
Figure 186: Ovarian Cancer, Global, Pipeline by Mechanism of Action, 2011 338
Figure 187: Ovarian Cancer, Global, Pipeline by Line of Therapy, 2011 339
Figure 188: Ovarian Cancer, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2011 341
Figure 189: Ovarian Cancer, Global, Technology Trends Description of Pipeline Drugs, 2011 341
Figure 190: Ovarian Cancer Pipeline by Phase of Clinical Development, 2011 342
Figure 191: Ovarian Cancer Therapeutics Market, Global, Avastin Sales Forecasts ($m), 2012-2020 353
Figure 192: Ovarian Cancer Therapeutics Market, Global, Paclical Sales Forecast ($m), 20122020 355
Figure 193: Ovarian Cancer Therapeutics Market, Global, Votrient Sales Forecast ($m), 20132020 357
Figure 194: Ovarian Cancer Therapeutics Market, Global, Farletuzumab Sales Forecast ($m), 2014-2020 359
Figure 195: Ovarian Cancer Therapeutics Market, Global, Karenitecin Sales Forecast ($m), 2014-2020 361
Figure 196: Ovarian Cancer Therapeutics Market, The US, Opaxio Sales Forecast ($m), 2014-2020 363
Figure 197: Ovarian Cancer Therapeutics Market, Global, AMG 386 Sales Forecast ($m), 20152020 365
Figure 198: Ovarian Cancer Therapeutics Market, Global, EC145 Sales Forecast ($m), 20162020 366
Figure 199: Ovarian Cancer Therapeutics Market, Global, Recentin Sales Forecast ($m), 20152020 368
Figure 200: Ovarian Cancer Therapeutics Market, Global, Vargatef Sales Forecast ($m), 2017-2020 370
Figure 201: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Status, March 2011 376
Figure 202: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Country, March 2011 377
Figure 203: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Phase, March 2011 378
Figure 204: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, March 2011 379
Figure 205: Ovarian Cancer Therapeutics Market, Global, Clinical Trials, Leading Sponsors, March 2011 380
Figure 206: Ovarian Cancer Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, March 2011 381
Figure 207: Ovarian Cancer Therapeutics Market, Global, Clinical Trials, Average Number of Patients Recruited, March 2011 382
Figure 208: Ovarian Cancer, F. Hoffmann-La Roche Ltd., SWOT Analysis 2011 384
Figure 209: Ovarian Cancer, Menarini Group, SWOT Analysis 2011 390
Figure 210: Ovarian Cancer, Global, GlaxoSmithKline, SWOT Analysis 2011 395
Figure 211: Ovarian Cancer, Eisai Inc., SWOT Analysis 2011 401
Figure 212: Ovarian Cancer, Cell Therapeutics, Inc., SWOT Analysis 2011 405
Figure 213: Ovarian Cancer, Amgen Inc., SWOT Analysis 2011 410
Figure 214: Ovarian Cancer, Global, AstraZeneca, SWOT Analysis 2011 415
Figure 215: Ovarian Cancer, Boehringer Ingelheim GmbH, SWOT Analysis 2011 420
Figure 216: Ovarian Cancer, Global, Key Data Inputs from KOL Interviews, 2011 427
Figure 217: GlobalData Market Forecasting Model 435
 

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *